These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 19304440)

  • 1. HER-family gene amplification and expression in resected pancreatic cancer.
    te Velde EA; Franke AC; van Hillegersberg R; Elshof SM; de Weger RW; Borel Rinkes IH; van Diest PJ
    Eur J Surg Oncol; 2009 Oct; 35(10):1098-104. PubMed ID: 19304440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coexpression of EGFR and HER-2 in pancreatic ductal adenocarcinoma: a comparative study using immunohistochemistry correlated with gene amplification by fluorescencent in situ hybridization.
    Dancer J; Takei H; Ro JY; Lowery-Nordberg M
    Oncol Rep; 2007 Jul; 18(1):151-5. PubMed ID: 17549361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
    Tsiambas E; Karameris A; Dervenis C; Lazaris AC; Giannakou N; Gerontopoulos K; Patsouris E
    JOP; 2006 May; 7(3):283-94. PubMed ID: 16685109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High expression of HER3 is associated with a decreased survival in gastric cancer.
    Hayashi M; Inokuchi M; Takagi Y; Yamada H; Kojima K; Kumagai J; Kawano T; Sugihara K
    Clin Cancer Res; 2008 Dec; 14(23):7843-9. PubMed ID: 19047113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
    Begnami MD; Fukuda E; Fregnani JH; Nonogaki S; Montagnini AL; da Costa WL; Soares FA
    J Clin Oncol; 2011 Aug; 29(22):3030-6. PubMed ID: 21709195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients.
    Morrison C; Zanagnolo V; Ramirez N; Cohn DE; Kelbick N; Copeland L; Maxwell GL; Fowler JM
    J Clin Oncol; 2006 May; 24(15):2376-85. PubMed ID: 16710036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma.
    Koka V; Potti A; Koch M; Fraiman G; Mehdi S; Levitt R
    Anticancer Res; 2002; 22(3):1593-7. PubMed ID: 12168842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression.
    Friess H; Yamanaka Y; Kobrin MS; Do DA; Büchler MW; Korc M
    Clin Cancer Res; 1995 Nov; 1(11):1413-20. PubMed ID: 9815939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Her-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness.
    Goebel SU; Iwamoto M; Raffeld M; Gibril F; Hou W; Serrano J; Jensen RT
    Cancer Res; 2002 Jul; 62(13):3702-10. PubMed ID: 12097278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis of the EGF-receptor family in pancreatic cancer: expression of HER-4 correlates with a favourable tumor stage.
    Thybusch-Bernhardt A; Beckmann S; Juhl H
    Int J Surg Investig; 2001; 2(5):393-400. PubMed ID: 12678544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amplification and overexpression of HER-2/neu in invasive ductal carcinomas of the pancreas and pancreatic intraepithelial neoplasms and the relationship to the expression of p21(WAF1/CIP1).
    Hermanová M; Lukás Z; Nenutil R; Brázdil J; Kroupová I; Kren L; Pazourková M; Růzicka M; Díte P
    Neoplasma; 2004; 51(2):77-83. PubMed ID: 15190415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR alterations in pancreatic ductal adenocarcinoma: a chromogenic in situ hybridization analysis based on tissue microarrays.
    Tsiambas E; Karameris A; Lazaris AC; Talieri M; Triantafillidis JK; Cheracakis P; Manaios L; Gerontopoulos K; Patsouris E; Lygidakis NJ
    Hepatogastroenterology; 2006; 53(69):452-7. PubMed ID: 16795991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of type 1 growth factor receptor expression in colon cancer.
    Leung SP; Griffith OL; Masoudi H; Gown A; Jones S; Phang T; Wiseman SM
    Am J Surg; 2008 May; 195(5):604-10. PubMed ID: 18424279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study.
    Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Bock JE; Glud E; Nørgaard-Pedersen B; Høgdall CK
    Cancer; 2003 Jul; 98(1):66-73. PubMed ID: 12833457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of c-erbB-2 oncogene protein, epidermal growth factor receptor, and TGF-beta1 in human pancreatic ductal adenocarcinoma.
    Zhang L; Yuan SZ
    Hepatobiliary Pancreat Dis Int; 2002 Nov; 1(4):620-3. PubMed ID: 14607699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers.
    Marx AH; Burandt EC; Choschzick M; Simon R; Yekebas E; Kaifi JT; Mirlacher M; Atanackovic D; Bokemeyer C; Fiedler W; Terracciano L; Sauter G; Izbicki JR
    Hum Pathol; 2010 Nov; 41(11):1577-85. PubMed ID: 20656317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma.
    Stoecklein NH; Luebke AM; Erbersdobler A; Knoefel WT; Schraut W; Verde PE; Stern F; Scheunemann P; Peiper M; Eisenberger CF; Izbicki JR; Klein CA; Hosch SB
    J Clin Oncol; 2004 Dec; 22(23):4737-45. PubMed ID: 15570074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term survival after radical resection for pancreatic head and ampullary cancer: a potential role for the EGF-R.
    Smeenk HG; Erdmann J; van Dekken H; van Marion R; Hop WC; Jeekel J; van Eijck CH
    Dig Surg; 2007; 24(1):38-45. PubMed ID: 17369680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptor-gamma and retinoid X receptor-alpha expression in pancreatic ductal adenocarcinoma: association with clinicopathological parameters, tumor proliferative capacity, and patients' survival.
    Giaginis C; Katsamangou E; Tsourouflis G; Zizi-Serbetzoglou D; Kouraklis G; Theocharis S
    Med Sci Monit; 2009 May; 15(5):BR148-56. PubMed ID: 19396032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of different members of the type 1 growth factor receptor family and their association with cell proliferation in periampullary carcinoma.
    Vaidya P; Kawarada Y; Higashiguchi T; Yoshida T; Sakakura T; Yatani R
    J Pathol; 1996 Feb; 178(2):140-5. PubMed ID: 8683379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.